Use of Terlipressin in AKI Associated with Hepatorenal Syndrome: PRO

What is it about?

Terlipressin is a newly approved therapy in the United States for hepatorenal syndrome, a severe form of acute kidney failure in patients with cirrhosis of the liver. The author argues for the adoption of terlipressin as the first-line agent of choice in treating hepatorenal syndrome.

Featured Image